# reload+after+2024-01-19 23:44:57.043891
address1§4960 Peachtree Industrial Boulevard
address2§Suite 240
city§Norcross
state§GA
zip§30071
country§United States
phone§678 620 3186
website§https://galectintherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
fullTimeEmployees§12
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Joel  Lewis', 'age': 53, 'title': 'President, CEO & Director', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 870664, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jack W. Callicutt CPA', 'age': 56, 'title': 'CFO, Treasurer & Corporate Secretary', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 492624, 'exercisedValue': 0, 'unexercisedValue': 4125}, {'maxAge': 1, 'name': 'Dr. Pol F. Boudes M.D., Ph.D.', 'age': 66, 'title': 'Chief Medical Officer', 'yearBorn': 1957, 'fiscalYear': 2022, 'totalPay': 720637, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Robert  Tritt', 'title': 'General Counsel', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jeff  Katstra', 'title': 'Head of CMC & Pharmaceutical Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Beth  Knowles', 'title': 'Executive Assistant & Officer Manager', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.939
currency§USD
dateShortInterest§1702598400
forwardEps§-0.66
exchange§NCM
quoteType§EQUITY
shortName§Galectin Therapeutics Inc.
longName§Galectin Therapeutics Inc.
firstTradeDateEpochUtc§1031146200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§7b109f3e-2059-3335-8b86-82e0d6c5f2dc
gmtOffSetMilliseconds§-18000000
recommendationMean§2.0
recommendationKey§buy
quickRatio§1.935
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
